Nektar Therapeutics (NKTR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $67.10 (-1.84%), Market cap $1.98B, 52-week low–high $0.49 ~ $73.86.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (T
Financial statements, price targets, institutional (13F) holdings and related news for Nektar Therapeutics are updated in real time on BlackAll Trade.
Nektar Therapeutics trades at $67.10 (-1.84%). Real-time quotes and charts are available on BlackAll Trade.
Nektar Therapeutics has a market cap of about $1.98B.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and int